Cell News and Research

RSS

Researchers engineering first-ever living, three-dimensional human arrhythmic tissue

A foundational study published in top biomedical journal PNAS (Proceedings of the National Academy of Sciences) this week by researchers at the University of Toronto's Institute of Biomaterials & Biomedical Engineering and the McEwen Centre for Regenerative Medicine have identified the optimal structure and cell ratio associated with heart function - and the discovery has already led the team to another research first: the engineering of the first-ever living, three-dimensional human arrhythmic tissue.

21 Nov 2013

New method uses lab-on-a-chip device and cell phone to determine concentration of molecules

In developing nations, rural areas, and even one's own home, limited access to expensive equipment and trained medical professionals can impede the diagnosis and treatment of disease.

21 Nov 2013

Buck Institute research provides method to study sarcopenia

Our epigenome is a set of chemical switches that turn parts of our genome off and on at strategic times and locations. These switches help alter the way our cells act and are impacted by environmental factors including diet, exercise and stress. Research at the Buck Institute reveals that aging also effects the epigenome in human skeletal muscle. The study, appearing on line in Aging Cell, provides a method to study sarcopenia, the degenerative loss of muscle mass that begins in middle age.

21 Nov 2013

Cedars-Sinai study presents new insights into mechanisms underlying the symptoms of autism

In what are believed to be the first studies of their kind, Cedars-Sinai researchers recording the real-time firing of individual nerve cells in the brain found that a specific type of neuron in a structure called the amygdala performed differently in people who suffer from autism spectrum disorder than in those who do not.

21 Nov 2013

Multiple sclerosis researchers receive NMSS drug development grant

A $500,000 drug development grant from the National Multiple Sclerosis Society was awarded to a partnership between a multiple sclerosis research team at the Icahn School of Medicine at Mount Sinai and Karyopharm Therapeutics Inc., a clinical stage pharmaceutical company. Dr. Patrizia Casaccia, MD, PhD, Professor in the Departments of Neuroscience and Genetics and Genomics, at Icahn School of Medicine at Mount Sinai, will be the academic lead.

21 Nov 2013

Researchers discover new human enzyme that facilitates DNA repair during DNA copying process

Every day, the human body produces new cells to regenerate tissues and repair those that have suffered injury. Each time this happens, the cells make copies of their DNA that they will pass on to the resulting daughter cells. This process of copying the DNA, also called replication, is very delicate, given that it can generate severe alterations in the DNA that are associated with malignant transformation or ageing.

21 Nov 2013

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

What we are trying to do is take a cancer model like the PDX model (patient-derived tumor xenograft), which is a human-derived cancer growing in an in vivo model and apply radiation to that model.

From Xstrahl 20 Nov 2013

DNA vaccine demonstrates potential to prevent and treat deadly MERS coronavirus

Inovio Pharmaceuticals, Inc. announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a SynCon DNA vaccine to prevent and treat this deadly virus.

20 Nov 2013

Parkinson's Institute, Population Diagnostics discover new genes relevant to Parkinson's disease

The Parkinson's Institute and Clinical Center announced today that they, in partnership with Population Diagnostics, Inc., have discovered a number of new genes relevant to the cause of Parkinson's disease.

20 Nov 2013

DNA-damaging drug and MK2 inhibitor combination could be effective against cancer

About half of all cancer patients have a mutation in a gene called p53, which allows tumors to survive and continue growing even after chemotherapy severely damages their DNA.

20 Nov 2013

Staphylococcus Aureus Bacteria anticipates and turns immune defenses against the host

Around 20 percent of all humans are persistently colonized with Staphylococcus aureus bacteria, a leading cause of skin infections and one of the major sources of hospital-acquired infections, including the antibiotic-resistant strain MRSA.

20 Nov 2013

Rapid DNA biochip tests for screening disease-causing bacteria

Patients affected by a bacterial infection can usually be treated with an antibiotic. But sometimes a resistant bacterial strain is causing the infection. In a hospital setting, doctors ideally want to know if they are dealing with such bacteria and which drugs they should choose. But if the doctor runs a test it can take days to get a result. Now, a European project is paving the way for much more rapid tests using DNA biochips. The aim is to rapidly screen disease-causing bacteria using a microarray to spot which resistant genes are present in bacteria.

20 Nov 2013

BioCardia reports positive results for Transendocardial Autologous Cells in Ischemic Heart Failure Trial

BioCardia, Inc., a leader in cardiovascular regenerative medicine, today announced positive 12-month results for the randomized Transendocardial Autologous Cells (MSC or BMC) in Ischemic Heart Failure Trial (TAC-HFT).

20 Nov 2013

Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases

Vect-Horus, a French company specialized in the development of vector molecules for the central nervous system, announces today it has signed a scientific collaboration agreement with Advanced Accelerator Applications, a fast growing international player in Molecular Nuclear Medicine. The financial terms of the deal have not been disclosed.

20 Nov 2013

Enhancing the NMDA glutamate receptor causes antidepressant-like effects

Thirteen years ago, an article in this journal first reported that the anesthetic medication, ketamine, showed evidence of producing rapid antidepressant effects in depressed patients who had not responded to prior treatments. Ketamine works by blocking one of the targets for the neurotransmitter glutamate in the brain, the N-methyl-D-aspartate (NMDA) glutamate receptor.

20 Nov 2013

Mount Sinai researchers win Best Manuscript Award for research on repair, reversal of heart attack damage

The Editors of the American Heart Association's (AHA) journal Circulation Research have awarded Icahn School of Medicine at Mount Sinai researchers a "Best Manuscript Award" for their investigations on repair and reversal of heart attack damage.

20 Nov 2013

Adding corticosteroid fluocortolone with standard therapy improves visual acuity in NAION patients

Nonarteritic anterior ischemic optic neuropathy is one of the leading causes of sudden and irreversible loss of vision in older adults. In a prospective randomized trial of 60 patients with NAION, investigators have shown that the addition of the corticosteroid fluocortolone to standard therapy significantly improves both short- and long-term visual acuity, especially when given soon after the onset of symptoms. Their results are published in Restorative Neurology and Neuroscience.

20 Nov 2013

First patients enrolled in EF-21 Study of NovoTTF Therapy for brain metastases from NSCLC cancer

Novocure announced today that the first patients have enrolled in the EF-21 Study, a prospective randomized clinical study of NovoTTF Therapy for patients with brain metastases from non-small cell lung carcinoma cancer. NovoTTF Therapy is an anti-mitotic treatment delivered continuously throughout the day by the NovoTTF-100A System.

20 Nov 2013

Researchers identify new way to improve heart repair

Researchers from the Baylor College of Medicine and the Texas Heart Institute have discovered a new way to dramatically improve heart repair. The future goal is to use this knowledge to combat human cardiovascular disease by improving repair after a heart attack. The research has just been published in the scientific journal Development.

20 Nov 2013

mTOR protein: A key mediator of antidepressant effects of ketamine

Two years ago, mammalian target of rapamycin or mTOR, a signaling protein, was identified as a key mediator of the antidepressant effects of ketamine, the first rapidly acting antidepressant medication to be identified.

20 Nov 2013

Cell News and Research

Researchers engineering first-ever living, three-dimensional human arrhythmic tissue

New method uses lab-on-a-chip device and cell phone to determine concentration of molecules

Buck Institute research provides method to study sarcopenia

Cedars-Sinai study presents new insights into mechanisms underlying the symptoms of autism

Multiple sclerosis researchers receive NMSS drug development grant

Researchers discover new human enzyme that facilitates DNA repair during DNA copying process

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

DNA vaccine demonstrates potential to prevent and treat deadly MERS coronavirus

Parkinson's Institute, Population Diagnostics discover new genes relevant to Parkinson's disease

DNA-damaging drug and MK2 inhibitor combination could be effective against cancer

Staphylococcus Aureus Bacteria anticipates and turns immune defenses against the host

Rapid DNA biochip tests for screening disease-causing bacteria

BioCardia reports positive results for Transendocardial Autologous Cells in Ischemic Heart Failure Trial

Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases

Enhancing the NMDA glutamate receptor causes antidepressant-like effects

Mount Sinai researchers win Best Manuscript Award for research on repair, reversal of heart attack damage

Adding corticosteroid fluocortolone with standard therapy improves visual acuity in NAION patients

First patients enrolled in EF-21 Study of NovoTTF Therapy for brain metastases from NSCLC cancer

Researchers identify new way to improve heart repair

mTOR protein: A key mediator of antidepressant effects of ketamine

How to optimize your cell line development eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms